Table 5.
The results of SUCRA in the subgroup analysis on patients without severe baseline grade.
| Treatment | 4-Week healing rate | 8-Week healing rate | ||||
|---|---|---|---|---|---|---|
| SUCRA | PrBest | MeanBank | SUCRA | PrBest | MeanBank | |
| Kev20 | 73.7 | 20.5 | 2.8 | 91.3 | 70.2 | 1.7 |
| Vpz40 | 90.7 | 73 | 1.7 | 76.2 | 14 | 2.9 |
| Lan30 | 74.2 | 4.5 | 2.8 | 66.6 | 0.7 | 3.7 |
| Rab20 | – | – | – | 63.7 | 14.5 | 3.9 |
| Vpz20 | 50 | 1.1 | 4.5 | 57.1 | 0.6 | 4.4 |
| Ome20 | 45.4 | 0.2 | 4.8 | 45.0 | 0.0 | 5.4 |
| Eso40 | 36.5 | 0.5 | 5.4 | 34.4 | 0.0 | 6.2 |
| Pan40 | 29.6 | 0.3 | 5.9 | 15.6 | 0.0 | 7.7 |
| Placebo | 0.0 | 0.0 | 8.0 | 0.1 | 0.0 | 9.0 |
Eso40, Esomeprazole 40 mg qd; Fex40, Fexuprazan 40 mg qd; Ila10, Ilaprazole 10 mg qd; Kev20, Keverprazan 20 mg qd; Lan30, Lansoprazole 30 mg qd; Lan60, Lansoprazole 60 mg qd; Ome 40, Omeprazole 40 mg qd; Ome 20, Omeprazole 20 mg qd; Pan40, Pantoprazole 40 mg qd; Rab10, Rabeprazole 10 mg bid; Rab20, Rabeprazole 20 mg qd; SUCRA, surface under the cumulative ranking curve; Teg100, Tegoprazan 100 mg qd; Teg50, Tegoprazan 50 mg qd; Vpz20, Vonoprazan 20 mg qd; Vpz40, Vonoprazan 40 mg qd.